GeoVax Labs Inc. (GOVX)
1.29
-0.06 (-4.44%)
At close: Mar 21, 2025, 3:59 PM
1.30
0.78%
After-hours: Mar 21, 2025, 06:55 PM EDT
-4.44% (1D)
| Bid | 1.25 |
| Market Cap | 12.17M |
| Revenue (ttm) | 4.71M |
| Net Income (ttm) | -35.83M |
| EPS (ttm) | -8.39 |
| PE Ratio (ttm) | -0.15 |
| Forward PE | -2.26 |
| Analyst | Buy |
| Ask | 1.38 |
| Volume | 473,432 |
| Avg. Volume (20D) | 661,067 |
| Open | 1.35 |
| Previous Close | 1.35 |
| Day's Range | 1.25 - 1.33 |
| 52-Week Range | 1.09 - 11.18 |
| Beta | 3.07 |
About GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, ch...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 25, 2020
Employees 17
Stock Exchange NASDAQ
Ticker Symbol GOVX
Website https://www.geovax.com
Analyst Forecast
According to 6 analyst ratings, the average rating for GOVX stock is "Buy." The 12-month stock price forecast is $16.5, which is an increase of 1179.07% from the latest price.
Stock ForecastsNext Earnings Release
GeoVax Labs Inc. is scheduled to release its earnings on Mar 27, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-16.92%
GeoVax Labs shares are trading lower. The company ...
Unlock content with
Pro Subscription
4 months ago
+3.5%
GeoVax Labs shares are trading lower. The company reported Q3 financial results.
